Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck (clinicaltrials.gov) - Oct 20, 2026 - P2 | N=65 | Terminated | Sponsor: Thomas Jefferson University | N=45 ➔ 65 | Active, not recruiting ➔ Terminated; Study was terminated early due to toxicity concerns by the Sponsor.
Enrollment change • IO biomarker • Trial termination • Head and Neck Cancer • Laryngeal Cancer • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1
|